ABT 101 - Alpha Beta Therapeutics
Alternative Names: ABT-101 - Alpha Beta TherapeuticsLatest Information Update: 03 Jul 2024
Price :
$50 *
At a glance
- Originator Alpha Beta Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Alpha Beta Therapeutics has patents pending for antibodies that trigger Macrophage-Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) (Alpha Beta Therapeutics website, April 2024)
- 05 Apr 2024 Preclinical trials in Cancer in USA (Parenteral)
- 05 Apr 2024 Pharmacodynamics data from a preclinical studies in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)